Estimation of the Various Urinary Biomarkers among the Non-Hypertensive Type 2 Diabetic Patients with Nephropathy

Introduction: Alteration in the various markers is seen in diabetic nephropathy (DN). In the current research, four different markers were evaluated and were examined for their diagnostic value in the nephropathic type 2 diabetes patients. Methods: A prospective clinical trial was piloted with diabetic male subjects with nephropathy. The subjects were followed up for 9 months. Thirty subjects were recruited as type 2 diabetes mellitus patients without nephropathy as controls. The interventional groups were grouped again as microalbuminuria, normoalbuminuria, and hyperfiltration. All of them underwent testing for urinary biomarkers like urine protein, ACR, HbA1C, and estimated glomerular filtration rate (eGFR). Correlation and logistic regression were used to compare all diagnostic tests across various groupings. Results: The greatest area under curve (AUC) values were .90 and .91 for AGT and AGT/Cr, respectively. The AUC, specificity, sensitivity, and cut-off value of AGT/Cr were, respectively, .91, 85%, 91%, and 4.36 mg/g. When using urine as the cut-off, the sensitivity was 42 and 100 for ACR and eGFR both. All other biomarkers had lower values than the AGT. Less than. 50 was evident for NGAL/Cr and NAGL. Conclusions: To identify DN, before the initiation of the albuminuria, compared to other diagnostic markers, urinary AGT demonstrated a greater diagnostic value. Further research is suggested to corroborate the findings

Auto-PAP titration efficacy in obstructive sleep apnea: A single-center experience

Introduction: Obstructive sleep apnea, often known as OSA, is a sleep-related breathing disease that, if not treated, can lead to serious disabilities or even death. Continuous positive airway pressure (CPAP) is the therapy technique that is suggested for treating severe and moderate OSA. An auto/manual CPAP titration study can be used to determine the appropriate pressure that must be maintained to treat this condition. The motive of this research is to appraise the effectiveness among OSA patients for the auto-PAP titrations. Methodology: A cross-sectional clinical prospective study was conducted at the tertiary care center. Subjects who underwent auto-PAP titration and had a diagnosis of moderate and sever OSA were included. They were evaluated for the efficacy of auto-PAP titration and other demographic features and their association with the titration efficacy. The values were compared for statistical significance. Results: The findings of the study showed that fifty percent of the cohort showed optimal titration, forty percent showed good titration, ten percent showed suitable titration, and none fell into the unacceptable group. Conclusion: According to the findings, using auto-PAP was associated with positive results in those with moderate and severe OSA. There is evidence to suggest that unattended auto-PAP titration is a very successful technique that might be regarded as a substitute for attended CPAP titrations. This would result in a reduction in the amount of labor required and the price

Assessment of Long-Term Pulmonary Function and Quality of Life in Patients with Chronic Obstructive Pulmonary Disease (COPD)

Background: Chronic obstructive pulmonary disease (COPD) is a prevalent respiratory condition portrayed by persistent airflow limitation and correlated symptoms. Despite advances in treatment, COPD remains a significant global health burden, necessitating ongoing research to understand its long-standing impact on pulmonary function and quality of life (QoL). Methods: This longitudinal research enrolled 200 COPD and followed them over a 5-year period. Baseline assessments included spirometry to measure forced expiratory volume in one second (FEV1) and forced vital capacity (FVC), along with standardized questionnaires assessing QoL. Follow-up assessments were conducted annually, and statistical analysis was performed to examine changes in pulmonary function and QoL over time. Results: Significant declines in FEV1 and FVC were observed at each follow-up time point compared to the baseline, indicating progressive deterioration in lung function. QoL scores, as assessed by the St. George’s Respiratory Questionnaire and the COPD Assessment Test, also worsened progressively over the research period. Conclusion: Current conclusions underscore the progressive nature of COPD, highlighting the importance of proactive management strategies aimed at preserving lung function and improving QoL. Early intervention and ongoing monitoring are essential in optimizing outcomes for COPD subjects and reducing the disease burden on individuals and healthcare systems

Correlation of ABO blood group susceptibility to Disease severity of SARS-COV-2: An original research

COVID-19, the Ecumenical Pandemic that hit Wuhan, Hubei Province, China, in 2019 has instigated an emergency situation all over the globe. Current scientific corroborations highlighted the role of zoonotic cross-over species transmission for the spread of the deadly virus SARSCoV2. The proposition of ABO blood grouping to susceptibility for various infectious diseases has been documented in the past since blood group antigens constitute polymorphic traits that are inherited among humans, therefore are frequent targets in epidemiological studies. Aim: To correlate the ABO blood group susceptibility to disease severity in COVID-19-positive cases among Indian populations. Objectives: Association of ABO blood group patterns to disease severity in COVID-19-positive cases. Materials and Methods: A cross-sectional, observational study design was conducted among 700 confirmed COVID-19-positive cases admitted to the tertiary health care center in Maharashtra, India. The data collected were subjected to statistical analysis. Results: Blood group 'A' positive was frequent (40%) in severe COVID-19 (E group) disease, and 'O' positive blood group was frequent in moderate COVID-19 disease (34.62%). Conclusion: ABO Blood grouping can be used as one of the efficient biomarker for COVID-19, thereby providing a new platform for therapeutic applications in the field of research